Phase II study of a combination of cisplatin and vindesine in malignant melanoma

Nineteen evaluable patients with advanced malignant melanoma have been treated with a combination of cisplatin 100 mg/m2 given as a 24-hr infusion on day 1 and vindesine 3 mg/m2 i.v. push on days 1, 8 and 15. Courses are repeated every 4 weeks. One complete and six partial responses have been achieved for an overall response rate of 37%. Effectiveness of this regimen seems to be unaffected by prior chemotherapy and visceral involvement. Median response duration has not yet been reached. Toxicity has been generally moderate, consisting mainly of gastro-intestinal intolerance. Further accrual and longer follow-up are needed to assess this regimen.SCOPUS: NotDefined.j